Abstract
Inflammation contributes to the severity of most diseases, and cytokine-specific blocking treatments are well established for autoinflammatory and autoimmune diseases. 1 Dinarello CA Simon A van der Meer JW Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012; 11: 633-652 Crossref PubMed Scopus (1136) Google Scholar However, cytokine-mediated inflammation also has a role in the pathogenesis of cancer; for example, in the immunosuppression of the disease. 2 Balkwill FR Mantovani A Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol. 2012; 22: 33-40 Crossref PubMed Scopus (474) Google Scholar Cytokine-mediated systemic inflammation is also a debilitating aspect of cancer. Many tumours produce inflammatory cytokines, which promote angiogenesis and tumour growth. Therefore, blocking a cytokine is a therapeutic option for treatment of cancer, particularly since anti-cytokine treatment lacks side-effects and tumours are unlikely to develop resistance to cytokine blockade. In The Lancet Oncology, David Hong and colleagues 3 Hong DS Hui D Bruera E et al. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014; (published online April 17.)http://dx.doi.org/10.1016/S1470-2045(14)70155-X Google Scholar report the effects of neutralising interleukin-1α in patients with end-stage cancers of various origins. The study is a unique contribution because it opens entire new areas in cancer therapeutics. The study also provides a rationale for early use of anti-cytokine therapy in cancer and sets the stage for use of anti-cytokine treatment in combination with kinase inhibitors and anti-immunosuppressive treatments. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion studyMABp1 was well tolerated, no dose-limiting toxicities were experienced in this study, and disease control was observed. Further study of MABp1 anti-interleukin-1α antibody therapy for advanced stage cancer is warranted. Full-Text PDF
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call